Innocare Pharma Ltd. Class A · SSE:688428
Innocare Pharma Ltd. Class A — H1 2020 Earnings Presentation
36 slides from Innocare Pharma Ltd. Class A's earnings presentation, August 2020
Slide 1: InnoCare Pharma 2020 Interim Presentation
InnoCare Pharma 2020 Interim Presentation Aug 2020
Slide 2: Disclaimer
Disclaimer These materials are for information purposes only and do not constitute or form part of an offer or invitation to sell or issue or the solicitation of an offer or invitation to buy or subscribe for securities of InnoCare Pharma Limited (the “Company”) or any of its holding company or subs
Slide 3: Our Vision
Our Vision To Become a Global Biopharmaceutical Leader that Develops and Delivers Innovative Therapies for Patients Worldwide Oncology Autoimmune Our Therapeutic Focus 2
Slide 4: InnoCare at a Glance
InnoCare at a Glance 1 Experienced founders and strong management team with an excellent track record 2 Fully integrated biopharmaceutical platform with strong in-house R&D capabilities 3 Worldwide rights to all product candidates Strategically focused pipeline of potential best/first-in-class targe
Slide 5: Fully-integrated Biopharma Company
Fully-integrated Biopharma Company 4 Clinical stage assets Drug Discovery Clinical Development − Potential best-in-class BTK All Products Developed In-house inhibitor targeting 2020 Unparalleled Clinical Execution • 90+ research scientists market launch • ~80 Clinical development personnel • Beijing
Slide 6: Top-notch Executives & Advisors
Top-notch Executives & Advisors • 20+ years of experience in research and development and • Elite Structural Biologist company management in the pharmaceutical industry • President and Founder of Westlake University • Former CEO and CSO of BioDuro, a PPD Company • Former Head of Early Development Te
Slide 7: Product Pipeline
Product Pipeline Balanced Drug Portfolio Targeting Both Proven and Novel Pathways Worldwide Pre-clinical Drug Target Indication(s) IND Phase I Phase II(2) Phase III NDA Filing Rights Development Accepted and given r/r CLL/SLL ✓ priority review status 1Q 2020 Accepted and given r/r MCL ✓ priority rev
Slide 8: Recent Development and Upcoming Milestones
Recent Development and Upcoming Milestones Orelabrutinib • Submitted two NDAs to the NMPA for r/r CLL/SLL and r/r MCL, both of which have been accepted and granted priority review earlier this year. Over 300 patients dosed with Orelabrutinib across all of our B-cell malignant cancer trials in total
Slide 9: Recent Development and Upcoming Milestones (cont’d)
Recent Development and Upcoming Milestones (cont’d) Other Clinical Candidates • ICP-192 Two patients with FGFR gene aberrations achieved partial responses and two patients with FGFR gene aberrations achieved stable disease in the dose escalation study Completed first patient dosing of phase II f
Slide 10: Key Pre-clinical Drug Candidates
Key Pre-clinical Drug Candidates In addition to our four clinical stage candidates, our pipeline includes more molecules at IND-enabling stage，of which three are considerable important to supplement our existing pipeline. ICP-332 ICP-189 ICP-490 ▪ A small-molecule inhibitor ▪ An oral allosteric inhi
Slide 11: Business Highlights
Section 1 Business Highlights
Slide 12: Orelabrutinib: Potential Best-in-class BTK Inhibitor Targeting B-cell Malignancies
1 Orelabrutinib (ICP-022) : Potential Best-in-class BTK Inhibitor Targeting B-cell Malignancies BTK Inhibitor: Large Market Potential • Bruton’s Tyrosine Kinase (“BTK”) is a key component of the B-cell receptor signaling pathway, which is an important regulator of cell proliferation and cell surviva
Slide 13: Orelabrutinib: Advantages and Highlights
1 Orelabrutinib (ICP-022) : Potential Best-in-class BTK Inhibitor Targeting B-cell Malignancies (cont’d) Advantages and Highlights Orelabrutinib is a potential best-in-class late-stage BTK inhibitor 1 Improved Target Selectivity Our “Point-of-Differentiation” Orelabrutinib Significant inhibition of
Slide 14: Improved Target Selectivity
1 Orelabrutinib (ICP-022) : Potential Best-in-class BTK Inhibitor Targeting B-cell Malignancies (cont’d) Improved Target Selectivity KINOMEscan dendrogram Orelabrutinib Ibrutinib Acalabrutinib Zanubrutinib • At 1 μM against 456 kinases in • At 1 μM concentration, ibrutinib • At 1 μM concentration, •
Slide 15: Favorable PK/PD Profile
1 Orelabrutinib (ICP-022) : Potential Best-in-class BTK Inhibitor Targeting B-cell Malignancies (cont’d) Favorable PK/PD Profile Post-dosing plasma exposure profile Orelabrutinib Ibrutinib(1) Acalabrutinib(1) Zanubrutinib(1) 1200 1200 1200 1200 1100 1100 1100 1100 1000 1000 1000 1000 Plasma Concentr
Slide 16: Better Target Occupancy
1 Orelabrutinib (ICP-022) : Potential Best-in-class BTK Inhibitor Targeting B-cell Malignancies (cont’d) Better Target Occupancy BTK occupancy Orelabrutinib Ibrutinib Acalabrutinib Zanubrutinib 100 100 100 90 80 90 B T K O c c u p a n c y (% ) BTK Occupancy (%) BTK Occupancy (%) 70 90 N=3 N=3 N=5 N=
Slide 17: Improved Safety and Robust Efficacy Profile
1 Orelabrutinib (ICP-022) : Potential Best-in-class BTK Inhibitor Targeting B-cell Malignancies (cont’d) Improved Safety and Robust Efficacy Profile Efficacy Profile Safety Profile 6-month DOR 77.1% 88.4% Adverse events Best response Best response of special orelabrutinib ibrutinib acalabrutinib zan
Slide 18: Rapid Clinical Development for Treatment of B-cell Malignancies
1 Orelabrutinib (ICP-022) : Potential Best-in-class BTK Inhibitor Targeting B-cell Malignancies (cont’d) Rapid Clinical Development for Treatment of B-cell Malignancies 80 patients completed enrollment in 10 months <1 yr to submit NDA from enrollment completion 2018 2018 Apr 2019 Feb 2019 Aug 2019 N
Slide 19: Orelabrutinib: Potential First-in-class BTK Inhibitor for Autoimmune Diseases
2 Orelabrutinib (ICP-022) : Potential First-in-class BTK Inhibitor for Autoimmune Diseases Prevalence of SLE and other major autoimmune diseases (RA, MS, Psoriasis and LN) expected to grow rapidly SLE Other major autoimmune diseases China Prevalence (MM) Global Prevalence (MM) China Prevalence (MM)
Slide 20: Robust Pre-clinical Efficacy Profile in Both SLE and RA
2 Orelabrutinib (ICP-022) : Potential First-in-class BTK Inhibitor for Autoimmune Diseases (Cont’d) Robust Pre-clinical Efficacy Profile in Both SLE and RA • Initiated a Phase Ib/IIa trial in combination with standard of care treatment for SLE in China, and completed first patient enrollment • Explo
Slide 21: FGFR Clinical and Market Potential
3 FGFR Clinical and Market Potential Market Potential Frequency of All Currently Known FGFR 1, 2, 3 and 4 Aberrations FGFR aberrations were found in 7.1% Glioma (~8%) of all solid tumors Head & Neck (~5%) Non-small Cell Lung (~5%) Source: Helsten et al., 2015, Clinical Cancer Research Thyroid / FGFR
Slide 22: ICP-192: Potential Best-in-class Pan-FGFR Inhibitor
3 ICP-192: Potential Best-in-class Pan-FGFR Inhibitor Favorable Pre-clinical Profile with Improved Target Selectivity and High FGFR Inhibitory Potency Kinase dendrogram shows improved target selectivity Favorable pre-clinical efficacy shown in multiple models harboring FGFR abnormalities 1 3 ICP-192
Slide 23: ICP-192: Potential Best-in-class Pan-FGFR Inhibitor (cont’d)
3 ICP-192: Potential Best-in-class Pan-FGFR Inhibitor (cont’d) Completed Phase I clinical trials and commenced Phase IIa clinical trials Advantages and Highlights 1 Improved Target Selectivity 2 High FGFR Inhibitory Potency 3 Favorable Pre-clinical Efficacy Profile 22
Slide 24: ICP-192: Clinical program
3 ICP-192: Potential Best-in-class Pan-FGFR Inhibitor (cont’d) One of the most advanced pan-FGFR inhibitors under clinical development in China Clinical program Phase I Completed • Two patients with FGFR gene aberrations achieved partial responses and two patients with FGFR gene aberrations achieved
Slide 25: ICP-105: Potential First-in-class FGFR4 Inhibitor
3 ICP-105: Potential First-in-class FGFR4 Inhibitor Robust Pre-clinical Profile ICP-105’s Clinical Program First-in-class Potential as FGFR4 inhibitor for HCC Ongoing and Planned Trials Phase I trial in China as a • Currently no marketed FGFR4 inhibitors globally monotherapy in solid tumor patients
Slide 26: ICP-723: Second Generation pan-TRK Inhibitor
4 ICP-723: Second Generation pan-TRK Inhibitor Distribution and frequency of NTRK fusions in adult1 Pre-clinical Results KM12 (carrying TPM3-NTRK1) Ba/F3 cells carrying LMNA- Cancers enriched for TRKA fusion and resistant TRK fusions mutation G595R Frequency > 90% V e h i c le , P O , B I D 1 st g e
Slide 27: Growth Strategies
~ NNOCARE ’ 5 ik ti % Section 2 Growth Strategies
Slide 28: Growth Strategies
Growth Strategies 1 Develop, commercialize and expand Orelabrutinib in B-cell malignancies Continue the development of ICP-192 and ICP-105 for solid tumors in China and 2 worldwide 3 Develop ICP-723 for solid tumors in China and worldwide 4 Develop Orelabrutinib and other potential candidates for au
Slide 29: Commercialization Strategy
Commercialization Strategy • In a Staggered Approach Corresponding with the Launch Timeline of Orelabrutinib • Already had over 40 sales and marketing figures on board James Deng Xiaodong Jin Sales & Marketing Advisor Chief Commercial Officer • GM of Becton • Sanofi (China) , GM of Dickinson’s Great
Slide 30: World-class Manufacturing Facility
World-class Manufacturing Facility To Meet Commercial Scale Production and Comply with GMP Requirements To Satisfy The Commercial Needs For At Least Next Five Years 46 Employees 65,000m2 + 30,000m2 Under construction Further expansion 1 2 Commercial-scale Pilot-scale OSD OSD Production Line Producti
Slide 31: Key Financials Updates
Key Financials Updates Research and Development Costs1 Administrative Expenses1 (RMB mm) 231 (RMB mm) 14 47 3 5 20 4 9 21 95 12 153 2 16 3 2 17 1 15 2 0 2 31 2 13 18 32 8 2019 H1 2020 H1 2019 H1 2020 H1 Employee Cost Share-Based Compensation Employee Cost Depreciation and amortisation Third Party Co
Slide 32: Other Information
Appendix Other Information
Slide 33: Income Statement
Income Statement For the six months ended 30 June1 RMB’000 2019 2020 1 1 Revenue 593 748 Revenue was mainly generated from providing research and development services to biopharmaceutical companies; no product sales Gross Profit 593 748 have been generated to date. Our sources of revenue are expecte
Slide 34: Balance Sheet
Balance Sheet As at 31 December June 30,1 RMB’000 FY2018 FY2019 2020 Non-Current Assets Property, Plant and Equipment 4,908 48,479 160,855 Goodwill 3,125 3,125 3,125 Other Intangible Assets 36,947 37,011 36,936 Right-of-use Assets 13,053 86,311 82,849 Investments in Joint Ventures 1,159 1,159 1,159
Slide 35: Balance Sheet (Cont’d)
Balance Sheet (Cont’d) As at 31 December June 30,1 RMB’000 FY2018 FY2019 1H2020 Current Liabilities Trade Payables 2,193 8,197 9,532 Loans and Borrowings 50,395 – – Other Payables and Accruals 5,397 41,528 50,510 Deferred Income 90 645 645 Lease Liabilities 5,332 6,204 5,506 Loans from a Related Par
Slide 36: Notes to Pipeline Chart
Notes to Pipeline Chart Notes: 1.Denotes the Company’s Core Product Candidate, orelabrutinib (ICP-022) 2.For indications of r/r CLL/SLL, r/r MCL and r/r WM, the registrational trial for NDA submission is the Phase II clinical trial based on the communications with the NMPA. Confirmatory Phase III cl